Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Q3 2020 Earnings Presentation
12 slides from Halozyme Therapeutics's earnings presentation, Nov 2, 2020
Slide 1: Third Quarter 2020 Financial Results Call
Third Quarter 2020 Financial Results Call November 2, 2020 Confidential and Proprietary
Slide 2: Safe Harbor
Safe Harbor In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance (including the Company's financial outlook for 2020) and expect
Slide 3: Return to Royalty Growth Primarily Driven by DARZALEX SC Launch
Return to Royalty Growth Primarily Driven by DARZALEX® SC Launch Quarterly Royalty Revenue ($M) Annual Royalty Revenue ($M) Projected Q3 2020 growth driven $80M–$85M by DARZALEX® SC utilizing ENHANZE® 79 23.9 70 16.6 17.2 16.8 15.8 $57M YTD Through Q3 Q3 Q4 Q1 Q2 Q3 2018 2019 2020 2019 2019 2020 202
Slide 4: Five Products Commercialized in Global Markets
Five Products Commercialized in Global Markets US ROW DARZALEX FASPROTM (daratumumab and hyaluronidase-fihj) Subcutaneous DARZALEX® (European approval June 2020) Confidential and Proprietary 4
Slide 5: 2020 Clinical Trial Progress: Anticipated New Trial Starts in 2020
2020 Clinical Trial Progress: 9 Anticipated New Trial Starts in 2020 3 Trials Initiated through October 2020 • Efgartigimod (phase 2) • Ipilimumab plus nivolumab (phase1) • CAPRISA (phase 1) 6 Additional Trials Projected to Start / Be Ready to Start in Q4 3 phase 3 studies 3 phase 1 studies • Efgart
Slide 6: Projected Milestones Drive Revenue and Free Cash Flow
Projected Milestones Drive Revenue and Free Cash Flow Milestone Revenue Projection 2019 2020 2021 2022 2018 $225 - $300M Projection 2019 Updated $350 - $450M Projection Actuals $60M $65M YTD Confidential and Proprietary 6
Slide 7: Capital Allocation Strategy
Capital Allocation Strategy Strong commitment to return capital to shareholders Priorities:: Potential Platform Drive ENHANZE Share Free Cash Flow Expansion via growth Repurchases M&A • Board-authorized share repurchase program for $550 • Maximize value of million over three years current collaborat
Slide 8: Third Quarter 2020 Revenue Highlights
Third Quarter 2020 Revenue Highlights1 $ U.S. in Millions (unaudited) 3Q 2020 3Q 2019 % Change Total Revenue $65.3 $46.2 41% Royalties $23.9 $16.6 44% Product Sales (incl. bulk rHuPH20 and ENHANZE® $9.0 $29.2 - Drug Product Sales, and Hylenex®(2) recombinant) Revenues under $32.3 $0.4 - collaborativ
Slide 9: Third Quarter 2020 Financial Highlights
Third Quarter 2020 Financial Highlights1 $ U.S. in Millions, except EPS (unaudited) 3Q 2020 3Q 2019 % Change Total Revenue $65.3 $46.2 41% Total Operating Expense $25.0 $70.8 (65%) Cost of Product Sales $5.6 $22.3 - R&D Expense $7.7 $30.5 (75%) SG&A Expense $11.7 $18.0 (35%) Net Income / (Loss) $36.
Slide 10: Increasing Full Year 2020 Financial Guidance
Increasing Full Year 2020 Financial Guidance Increasing 2020 Revenue Guidance to $250M-$260M from $230M-$245M* First 9-months of Full Year Drivers 2020 Guidance* Royalties $56.6M $80M - $85M • DARZALEX® SC launch Revenue Under • New study starts $65.8M $115M - $120M Collaborations • Commercial Produ
Slide 11: Value-driving Events Anticipated in 2020
Value-driving Events Anticipated in 2020 ❑ U.S. Launch of DARZALEX FASPROTM ❑ Sustainable profitability beginning in Q2 ❑ EU approval and launch of SC daratumumab ❑ US FDA Approval and US Launch of Phesgo® ❑ Return to growth in revenue from royalties ❑ 9 new clinical trial starts: ON TRACK ❑ Includi
Slide 12: Third Quarter 2020 Financial Results Call
Third Quarter 2020 Financial Results Call November 2, 2020 Confidential and Proprietary
Halozyme Therapeutics — Q3 2020 Earnings Presentation on 6ix